Johnson & Johnson JNJ
Johnson & Johnson (NYSE: JNJ) is an oncology drug developer. Its lead program, DARZALEX (daratumumab), is marketed for Multiple myeloma.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DARZALEX (daratumumab) | Multiple myeloma | antibody | Approved |
| CARVYKTI (ciltacabtagene autoleucel) | Multiple myeloma | cell therapy | Approved |
| TECVAYLI (teclistamab-cqyv) | Multiple myeloma | antibody | Approved |
| TALVEY (talquetamab-tgvs) | Multiple myeloma | antibody | Approved |
| RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) | NSCLC | antibody/small molecule | Approved |
| ERLEADA (apalutamide) | Prostate cancer | small molecule | Approved |
| INLEXZO (gemcitabine intravesical system) | Bladder cancer | drug-device combination | Approved |
| TREMFYA (guselkumab) | Psoriasis/IBD | antibody | Approved |
| STELARA (ustekinumab) | Psoriasis/IBD | antibody | Approved |
| SPRAVATO (esketamine) | Depression | small molecule | Approved |
| CAPLYTA (lumateperone) | Major Depressive Disorder/bipolar/schizophrenia | small molecule | Approved |
| IMAAVY (nipocalimab) | Immunology | antibody | Approved |
Recent results and decisions
- Apr 14, 2026approval FDA approved ICOTYDE, a targeted oral peptide, for moderate to severe plaque psoriasis.
FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Filing - Apr 14, 2026approval FDA approved TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma as early as second line.
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Filing - Apr 14, 2026approval FDA approved RYBREVANT FASPRO, the only EGFR-targeted therapy administered once a month.
FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.